Meritage Portfolio Management’s iShares Biotechnology ETF IBB Stock Holding History

Meritage Portfolio Management’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-38,680	Closed	-$4.52M	–	317
2022 Q3	$4.52M	Buy	+38,680	New	+$4.8M	0.37%	79
2018 Q2	–	Sell	-101,826	Closed	-$10.9M	–	215
2018 Q1	$10.9M	Buy	101,826 +2,282	+2%	+$253K	1.05%	15
2017 Q4	$10.6M	Sell	99,544 -1,724	-2%	-$184K	1.02%	15
2017 Q3	$11.3M	Buy	101,268 +435	+0.4%	+$46.5K	1.1%	13
2017 Q2	$10.4M	Sell	100,833 -2,421	-2%	-$238K	1.07%	13
2017 Q1	$10.1M	Sell	103,254 -1,839	-2%	-$176K	1.06%	16
2016 Q4	$9.3M	Buy	+105,093	New	+$9.56M	1.02%	18

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

AWA

Arete Wealth Advisors Chicago, Illinois $1.51B AUM 33.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

CANY

Caxton Associates (New York) New York $3.18B AUM 54.49% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Meritage Portfolio Management's IBB Position: Q4 2022 in Review

Meritage Portfolio Management sold out of iShares Biotechnology ETF (IBB) in Q4 2022, closing a stake of 38,680 shares — an estimated $4.52M sold.

Meritage Portfolio Management first reported a position in IBB in Q4 2016 and held it in 7 quarters. The position peaked at $11.3M in Q3 2017. 903 funds tracked by Wall St. Rank hold IBB as of Q4 2022.

Meritage Portfolio Management reported no remaining iShares Biotechnology ETF position as of Q4 2022 after selling out during the quarter.
Meritage Portfolio Management sold 38,680 iShares Biotechnology ETF shares in Q4 2022, an estimated $4.52M.
Meritage Portfolio Management first reported a position in iShares Biotechnology ETF in Q4 2016 and held it in 7 quarters.
Meritage Portfolio Management's iShares Biotechnology ETF position peaked at $11.3M in Q3 2017.
903 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q4 2022.

Based on Meritage Portfolio Management's 13F filing for Q4 2022, filed 1 Feb 2023.